CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ayala Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ayala Pharmaceuticals Inc
9 DEER PARK DRIVE, SUITE K-1
Phone: (609) 452-9813p:609 452-9813 MONMOUTH JUNCTION, NJ  08852  United States Ticker: ADXSADXS
This company ceased filing statements with the SEC on 5/9/2024.
Business Summary
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board DavidSidransky 64 5/27/2015 7/16/2013
President, Chief Executive Officer, Director Kenneth A.Berlin 58 5/1/2022 4/23/2018
Independent Vice Chairman of the Board VeredBisker-leib 53 1/19/2023 1/19/2023
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
BioSight, Ltd. 152., Begin St. Tel Aviv Israel

Business Names
Business Name
Advaxis Inc.
Advaxis, Inc.
ADXS
ADXSD
BioSight, Ltd.

General Information
Number of Employees: 20 (As of 12/31/2023)
Outstanding Shares: 42,633,400 (As of 4/8/2024)
Shareholders: 117
Stock Exchange: OTC
Federal Tax Id: 841521955
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024